Complex assessment of Latanoprost use in clinical practice: the results of a questionnaire survey
https://doi.org/10.25700/NJG.2019.03.02
Abstract
Primary open-angle glaucoma is a chronic optic neuropathy, which often requires a lifelong treatment. Patient compliance, adherence to therapy and persistence play a vital role in improving the outcomes by reducing morbidity and the economic consequences that are associated with disease progression.
PURPOSE: To assess the role of Xalatan use in modern conservative drug therapy of glaucoma process.
METHODS: A non-clinical, epidemiological, single-step study was conducted by interviewing 231 outpatient ophthalmologists in 19 cities of the Russian Federation. RESULTS: Data analysis allowed us to conclude that Xalatan presently is one of the leading prostaglandin ana logues prescribed by ophthalmologists on the territory
of the Russian Federation.
CONCLUSION: After assessing the number of cases of insufficient Xalatan efficacy, we could conclude that doctors are highly satisfied with the treatment results. At the same time, the frequency of choosing Xalatan as the first line drug, second line drug, as well as total percentage of patients receiving Xalatan, and the number of patients who had to cancel Xalatan due to lack of effectiveness did not depend on the doctor’s experience, which indicates that doctors were highly aware of Xalatan.
About the Authors
I. A. Loskoutov
Science clinical center Russian railways (Ophthalmology Department)
Russian Federation
Russian Federation
Med.Sc.D., Professor, Head of Ophthalmology Dept
84 Volokolamsk highway, Moscow, 123567
A. V. Korneeva
LLC «Tri-Z-MSK»
Russian Federation
Russian Federation
Ph.D., Ophthalmologist
3 Borisa Galushkina Str., Moscow, 129301
References
1. Resnikoff S., Pascolini D., Etya’ale D., Kocur I. et al. Global data on visual impairment in the year 2002. Bull World Health Organ. 2004; 82(11):844–851. doi:S0042-96862004001100009
2. Quigley H.A., Broman A.T. The number of people with glaucoma worldwide in 2010 and 2020. Br J Ophthalmol. 2006; 90(3):262-267. doi: 10.1136/bjo.2005.081224
3. Heijl A., Bengtsson B., Chauhan B.C., Lieberman M.F. et al. A comparison of visual field progression criteria of 3 major glaucoma trials in early manifest glaucoma trial patients. Ophthalmology. 2008; 115:1557–1565. doi:10.1016/j. ophtha.2008.02.005
4. Gillespie B.W., Musch D.C., Guire K.E., Mills R.P. et al. CIGTS (Collaborative Initial Glaucoma Treatment Study) Study Group. The collaborative initial glaucoma treatment study: Baseline visual field and test-retest variability. Invest Ophthalmol Vis Sci. 2003; 44:2613–2620. doi:10.1167/iovs.02-0543
5. Ernest P.J., Schouten J.S., Beckers H.J., Hendrikse F. et al. An evidence-based review of prognostic factors for glaucomatous visual field progression. Ophthalmology. 2013; 120:512–519. doi:10.1016/j.ophtha.2012.09.005
6. Bagnis A., Papadia M., Scotto R., Traverso C.E. Current and emerging medical therapies in the treatment of glaucoma. Expert Opin Emerg Drugs. 2011; 16(2):293–307. doi: 10.1517/14728214.2011.563733
7. Curran M.P., Orman J.S. Bimatoprost/timolol: a review of its use in glaucoma and ocular hypertension. Drugs Aging. 2009; 26(2): 169–184. doi: 10.2165/0002512-200926020-00008
8. Chauhan B.C., Mikelberg F.S., Balaszi A.G. et al. Canadian glaucoma study: risk factors for the progression of open-angle glaucoma. Arch Ophthalmol. 2008; 126(8):1030–1036. doi: 10.1001/archopht.126.8.1030
9. Heijl A., Leske M.C., Bengtsson B. et al. Reduction of intraocular pressure and glaucoma progression: results from the early manifest glaucoma trial. Arch Ophthalmol. 2002; 120(10):1268–1279.
10. Garway-Heath D.F., Crabb D.P., Bunce C., Lascaratos G. et al. Latanoprost for open-angle glaucoma (UKGTS): A randomised, multicentre, placebo-controlled trial. Lancet. 2015; 385:1295–1304. doi:10.1016/ S0140-6736(14)62111-5
11. van der Valk R., Webers C.A., Schouten J.S., Zeegers M.P. et al. Intraocular pressure-lowering effects of all commonly used glaucoma drugs: A meta-analysis of randomized clinical trials. Ophthalmology. 2005; 112:1177–1185.
12. European Glaucoma Society. Terminology and Guidelines for Glaucoma. 4th ed. Savona, Italy: PubliComm; 2014. doi:10.1136/bjophthalmol-2016-egsguideline.001
13. Stjernschantz J., Resul B. Phenyl substituted prostaglandin analogsfor glaucoma treatment. Drugs Future. 1992; 17:691-704. doi:10.1358/ dof.1992.017.08.187766
14. Aung T., Chan Y.H., Chew P.T. EXACT Study Group. Degree of angle closure and the intraocular pressure-lowering effect of latanoprost in subjects with chronic angle-closure glaucoma. Ophthalmology. 2005; 112:267–271. doi:10.1016/j.ophtha.2004.08.024.
15. Boland M.V., Ervin A.M., Friedman D.S., Jampel H.D. et al. Comparative effectiveness of treatments for open-angle glaucoma: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med. 2013; 158:271-279. doi:10.7326/0003-4819-158-4-20130219000008
16. Lin L., Zhao Y.J., Chew P.T., Sng C.C. et al. Comparative efficacy and tolerability of topical prostaglandin analogues for primary openangle glaucoma and ocular hypertension. Ann Pharmacother. 2014; 48(12):1585-1593. doi:10.1177/1060028014548569
17. Cucherat M., Stalmans I., Rouland J.F. Relative efficacy and safety of preservative-free latanoprost (T2345) for the treatment of openangle glaucoma and ocular hypertension: an adjusted in direct comparison meta-analysis of randomized clinical trials. J Glaucoma. 2014; 23:69-75. doi:10.1097/IJG.0b013e3182a075e6
18. Eyawo O., Nachega J., Lefebvre P., Meyer D. et al. Efficacy and safety of prostaglandin analogues in patients with predominantly primary open-angle glaucoma or ocular hypertension: a meta-analysis. Clin Ophthalmol. 2009; 3:447-456. doi:10.2147/opth.s6501
19. Honrubia F., Garcia-Sánchez J., Polo V., Martinez J.M. et al. Conjunctival hyperaemia with the use of latanoprost versus other prostaglandin analogues in patients with ocular hypertension or glaucoma: a meta-analysis of randomised clinical trials. Br J Ophthalmol. 2009; 93:316-321. doi:10.1136/bjo.2007.135111
20. Orme M., Collins S., Dakin H., Kelly S. et al. Mixed treatment comparison and meta-regression of the efficacy and safety of prostaglandin analogues and comparators for primary open-angle glaucoma and ocular hypertension. Curr Med Res Opin. 2010; 26:511-528. doi:10.1185/03007990903498786
21. Kara C., Şen E.M., Elgin K.U., Serdar K. et al. Does the intraocular pressurelowering effect of prostaglandin analogues continue over the long term? Int Ophthalmology. 2017; 37(3):619-626. doi:10.1007/ s10792-016-0315-3
22. National Guide to Glaucoma: for Practitioners. Ed by E.A. Egorov, Yu.S. Astakhov, V.P. Erichev. Moscow: GEOTAR-Media; 2015: 190-197. (In Russ.). http://www.glaucomanews.ru/files/glaukoma_wm.pdf
23. American Academy of Ophthalmology Glaucoma Panel. Primary open-angle glaucoma suspect. San Francisco (CA): American Academy of Ophthalmology; 2010.
24. Connor A.J., Fraser S.G. Glaucoma prescribing trends in England 2000 to 2012. Eye (Lond). 2014; 28:863-869. doi:10.1038/ eye.2014.114
25. Schmier J.K., Lau E.C., Covert D.W. Two-year treatment patterns and costs in glaucoma patients initiating treatment with prostaglandin analogs. Clin Ophthalmol. 2010; 4:1137-1143. doi:10.2147/OPTH. S13884
26. Daka Q., Trkulja V. Efficacy and tolerability of mono-compound topical treatments for reduction of intraocular pressure in patients with primary open angle glaucoma or ocular hypertension: an overview of reviews. Croat Med J. 2014; 55(5):468-480. doi:10.3325/ cmj.2014.55.468
27. WHO web link: http://www.who.int/medicines/publications/essentialmedicines/EML2015_8-May-15.pdf.
28. Neroev V.V., Kiseleva O.A., Bessmertnyj A.M. The main results of a multicenter study of epidemiological features of primary open-angle glaucoma in the Russian Federation. Rossijskij oftal’mologicheskij zhurnal. 2013; 6(3):43–46. (In Russ.).
Review
For citations:
Loskoutov I.A., Korneeva A.V. Complex assessment of Latanoprost use in clinical practice: the results of a questionnaire survey. National Journal glaucoma. 2019;18(3):20-28. (In Russ.) https://doi.org/10.25700/NJG.2019.03.02
Views:
604
Email this article 